Abstract
In 2019, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted via airborne route, caused a new pandemic namely, “coronavirus disease 2019” (COVID-19). Although it is still debated whether the use of masks can prevent the transmission of SARS-CoV-2, no study has evaluated the virus-blocking efficacy of masks used by patients. We aimed to evaluate this efficacy of masks used by SARS-CoV-2-infected individuals. Data, masks used, and nasopharyngeal swab samples were obtained from these patients. Forty-five paired samples of nasopharyngeal swabs and masks were obtained and processed; the majority of masks were woven. Viral RNAs were amplified using quantitative reverse-transcription polymerase chain reaction and detected only on the inner parts of masks. Median cycle threshold (Ct) values of swabs and masks were 28.41 and 37.95, respectively. Statistically, there was a difference of approximately 10 Ct values between swabs and masks and no significant difference in Ct values among different types of masks. There were statistically significant differences in Ct values between men and women and symptomatic and asymptomatic patients. Our findings suggest the blocking of the transmission of viruses by different types of masks and reinforce the use of masks by both infected and non-infected individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Fiocruz Promote Innovation Program, 'Inova Fiocruz', through Oswaldo Cruz Foundation and Science, Technology and Strategic Inputs Secretariat of Brazilian Ministry of Health. And funded by the Brazilian national funding agency 'Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior do Brasil / CAPES', under finance code 001.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by Ethics Committee of the Oswaldo Cruz Insti-tute/IOC/FIOCRUZ (protocol code: CAAE 37142520.0.0000.5248 approved on September 30, 2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
I agree to provide the data if necessary and requested
